- Home
- RDCM vs ADCT Comparison
RDCM vs ADCT Comparison
Compare RDCM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- ADCT
- Stock Information
- Founded
- RDCM 1985
- ADCT 2011
- Country
- RDCM Israel
- ADCT Switzerland
- Employees
- RDCM N/A
- ADCT N/A
- Industry
- RDCM Computer peripheral equipment
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- ADCT Health Care
- Exchange
- RDCM Nasdaq
- ADCT Nasdaq
- Market Cap
- RDCM 206.0M
- ADCT 241.0M
- IPO Year
- RDCM 1997
- ADCT 2020
- Fundamental
- Price
- RDCM $14.50
- ADCT $3.28
- Analyst Decision
- RDCM Strong Buy
- ADCT Strong Buy
- Analyst Count
- RDCM 2
- ADCT 6
- Target Price
- RDCM $16.00
- ADCT $7.80
- AVG Volume (30 Days)
- RDCM 85.4K
- ADCT 733.2K
- Earning Date
- RDCM 08-13-2025
- ADCT 08-05-2025
- Dividend Yield
- RDCM N/A
- ADCT N/A
- EPS Growth
- RDCM 111.69
- ADCT N/A
- EPS
- RDCM 0.53
- ADCT N/A
- Revenue
- RDCM $63,477,000.00
- ADCT $75,817,000.00
- Revenue This Year
- RDCM $18.09
- ADCT $11.75
- Revenue Next Year
- RDCM $11.46
- ADCT $10.29
- P/E Ratio
- RDCM $27.41
- ADCT N/A
- Revenue Growth
- RDCM 18.21
- ADCT 10.49
- 52 Week Low
- RDCM $9.19
- ADCT $1.05
- 52 Week High
- RDCM $15.98
- ADCT $3.98
- Technical
- Relative Strength Index (RSI)
- RDCM 61.15
- ADCT 57.96
- Support Level
- RDCM $13.49
- ADCT $2.98
- Resistance Level
- RDCM $14.50
- ADCT $3.19
- Average True Range (ATR)
- RDCM 0.72
- ADCT 0.22
- MACD
- RDCM 0.11
- ADCT 0.01
- Stochastic Oscillator
- RDCM 95.24
- ADCT 84.63
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).